Gender Disparity in Receipt of End-of-Life Care

Share this content:
There are gender differences in receipt of end-of-life care among terminally ill cancer patients.
There are gender differences in receipt of end-of-life care among terminally ill cancer patients.

There are gender differences in receipt of end-of-life (EoL) care among terminally ill cancer patients, with male patients more likely to receive intensive care unit (ICU) care, according to a study published in Cancer.

Rashmi K. Sharma, M.D., from Northwestern University in Chicago, and colleagues conducted a multisite, prospective cohort study involving 353 patients with metastatic cancers who were identified as terminally ill at study enrollment. Participants were interviewed at a median of 4.1 months before their death.

The authors examined whether gender differences exist in the receipt of ICU care and the correlation between EoL discussions and receipt of EoL ICU care.

The researchers found that male patients were more likely to receive ICU care at the EoL (73 versus 52 percent; P = 0.02).

Male patients reporting an EoL discussion were less likely than those not reporting a discussion to have an ICU stay in the last week of life, after adjustment for potential confounders (adjusted odds ratio, 0.26; P = 0.04). 

RELATED: Palliative Chemo for Terminal Cancer Tied to Death in ICU

Among female patients there was no correlation between EoL discussions and ICU stays near death.

"Gender differences in the effects of EoL discussions on EoL care likely contribute to and may even explain gender differences in the receipt of ICU care in the last week of life," the authors write.

Reference

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters